OSU K12 Training Grant in Oncology
OSU K12 Training Grant in Oncology
批准号:
10477991
负责人:
WILLIAM E. CARSON
金额:
$81.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-09 至 2024-06-30
关键词:
Applied ResearchAreaBasic ScienceClinicalClinical InvestigatorClinical ResearchClinical TrialsComprehensive Cancer CenterDisciplineDoctor of PhilosophyEnsureFacultyFinancial SupportGoalsGrantHematologyIndividualInvestigationInvestigational TherapiesLaboratoriesMalignant NeoplasmsMedical OncologyMedicineMentored Clinical Scientist Development ProgramMentorsMinority GroupsOhioOncologyPaperPeer ReviewProgram EvaluationRadiation OncologyResearchResearch PersonnelResourcesSECTM1 geneStructureSurgical OncologyTrainingTraining ProgramsUnderserved PopulationUniversitiesWomen&aposs Groupanticancer researchbasecancer diagnosiscancer preventioncareercareer developmentdrug developmenteducation researcheffectiveness evaluationinterestlaboratory developmentprogramsrecruitsuccesssurvivorshiptranslational cancer researchtranslational scientist
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
The goal of this proposal is to mentor and train junior faculty investigators in laboratory and/or clinical translational
cancer research. Implementation of this K12 program for the career development of laboratory-based
(PhD/DVM/MD) and clinical (MD or MD/PhD) translational scientists in diverse areas of oncology will ensure a
cadre of highly-trained individuals who can communicate across disciplines to drive new advancements in how
we approach cancer diagnosis and management. This K12 program from The Ohio State University
Comprehensive Cancer Center (OSUCCC) continues its focus on early drug development, but now also extends
to cancer prevention, control and survivorship research. The OSUCCC is clearly dedicated to research education
and providing outstanding career development and mentoring opportunities to promising junior faculty. The
Divisions of Hematology, Medical Oncology, Radiation Oncology, and Surgical Oncology each have robust
programs that are continuously recruiting new junior faculty to facilitate expansion of our cancer program.
Recruitment efforts also emphasize the inclusion of women, minorities and underserved groups to increase
diversity. This K12 grant fills an important need by extending research education, career development and
mentoring to junior faculty interested in establishing academic research careers. It is the only OSUCCC training
program dedicated solely to faculty-level career development in cancer research, and thus has no overlap with
any of the OSU T32 training grants, which focus on fellows. This strategy ensures continuity in training and
provides individuals a structured path to become independent clinical or translational investigators. The quality
of this K12 program and its success in training cancer researchers is exemplified by the career trajectories of
past trainees, their papers, grants, clinical trials and other scholarly activities that have driven new discoveries.
The continued success of this program will be ensured by the overall strength and direction of the OSUCCC, as
demonstrated by its recent peer review score of 10 (exceptional), financial support of this K12 program by the
OSUCCC and by different Divisions and Departments, and the enormous breadth of expertise and resources
available at OSU. This K12 program seeks to train two types of investigators. The first includes MD and/or PhD
faculty who have outstanding basic science training and want to pursue laboratory-based investigation related
to applied research in experimental therapeutics, cancer prevention, control, and survivorship. The second group
includes MD or MD/PhD faculty who want to pursue clinical research in experimental therapeutics and cancer
prevention, control, or survivorship. Training plans are tailored to each individual trainee to facilitate their
success, with inclusion of a robust evaluation program to assess the effectiveness of the K12. The value of the
OSU K12 program is best demonstrated by nearly all of the current and past K12 scholars remaining in academic
medicine and moving forward as independent laboratory or clinical investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
-
批准号:10711488
-
项目类别:
-
资助金额:$58.72万
-
财政年份:2023
-
负责人:WILLIAM E. CARSON
-
依托单位:
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment
-
批准号:9166825
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2016
-
负责人:WILLIAM E. CARSON
-
依托单位:
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment
-
批准号:9763480
-
项目类别:
-
资助金额:$54.32万
-
财政年份:2016
-
负责人:WILLIAM E. CARSON
-
依托单位:
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment
-
批准号:10006088
-
项目类别:
-
资助金额:$50.7万
-
财政年份:2016
-
负责人:WILLIAM E. CARSON
-
依托单位:
Cetuximab Therapy of Pancreatic Cancer: Immune Modulation with IL-21
-
批准号:7740058
-
项目类别:
-
资助金额:$19.8万
-
财政年份:2009
-
负责人:WILLIAM E. CARSON
-
依托单位:
OSU K12 Training Grant in Oncology
-
批准号:10224104
-
项目类别:
-
资助金额:$79.74万
-
财政年份:2008
-
负责人:WILLIAM E. CARSON
-
依托单位:
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21
-
批准号:7313944
-
项目类别:
-
资助金额:$39.21万
-
财政年份:2007
-
负责人:WILLIAM E. CARSON
-
依托单位:
Therapy of Melanoma with Bortezomib and Interferon-alpha
-
批准号:7418854
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2006
-
负责人:WILLIAM E. CARSON
-
依托单位:
Therapy of Melanoma with Bortezomib and Interferon-alpha
-
批准号:7056407
-
项目类别:
-
资助金额:$26.54万
-
财政年份:2006
-
负责人:WILLIAM E. CARSON
-
依托单位:
Therapy of Melanoma with Bortezomib and Interferon-alpha
-
批准号:7230025
-
项目类别:
-
资助金额:$25.77万
-
财政年份:2006
-
负责人:WILLIAM E. CARSON
-
依托单位:
Modulation of Tumor CEA Levels for an Anti-CEA Vaccine
-
批准号:7067110
-
项目类别:
-
资助金额:$28.83万
-
财政年份:2005
-
负责人:WILLIAM E. CARSON
-
依托单位:
Modulation of Tumor CEA Levels for an Anti-CEA Vaccine
-
批准号:6932740
-
项目类别:
-
资助金额:$29.53万
-
财政年份:2005
-
负责人:WILLIAM E. CARSON
-
依托单位:
PHASE I TRIAL OF INTERLEUKIN-12 IN COMBINATION WITH PACLITAXEL PLUS HERCEPTIN
-
批准号:7198628
-
项目类别:
-
资助金额:$3.21万
-
财政年份:2004
-
负责人:WILLIAM E. CARSON
-
依托单位:
Phase I Trial of IL-12 with Paclitaxel Plus Herceptin
-
批准号:7011512
-
项目类别:
-
资助金额:$22.17万
-
财政年份:2003
-
负责人:WILLIAM E. CARSON
-
依托单位:
A program of immune-based treatments for cancer
-
批准号:7385294
-
项目类别:
-
资助金额:$17.83万
-
财政年份:2002
-
负责人:WILLIAM E. CARSON
-
依托单位:
A Program of Immune-Based Treatments for Cancer
-
批准号:6615541
-
项目类别:
-
资助金额:$15.04万
-
财政年份:2002
-
负责人:WILLIAM E. CARSON
-
依托单位:
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21
-
批准号:7916683
-
项目类别:
-
资助金额:$40.83万
-
财政年份:2002
-
负责人:WILLIAM E. CARSON
-
依托单位:
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21
-
批准号:8325703
-
项目类别:
-
资助金额:$40.1万
-
财政年份:2002
-
负责人:WILLIAM E. CARSON
-
依托单位:
A program of immune-based treatments for cancer
-
批准号:7790710
-
项目类别:
-
资助金额:$18.23万
-
财政年份:2002
-
负责人:WILLIAM E. CARSON
-
依托单位:
Tumor Immunology
-
批准号:10020920
-
项目类别:
-
资助金额:$15.35万
-
财政年份:2002
-
负责人:WILLIAM E. CARSON
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: